Recombinant Human GPA Protein, Active
Beta LifeScience
SKU/CAT #: BLK-02055P-100UG
Human GPA on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Recombinant Human GPA Protein, Active
Beta LifeScience
SKU/CAT #: BLK-02055P-100UG
Collections: Other recombinant proteins, Recombinant proteins
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Human GPA Protein is expressed from HEK293 with hFc tag at the C-Terminus.It contains Ser20-Glu91. |
Purity | > 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
Accession | P02724 |
Target Symbol | GPA |
Synonyms | Glycophorin-A; PAS-2; CD235a; glycophorin Erik; glycophorin MiI; glycophorin MiIII; glycophorin MiV; glycophorin MiX; glycophorin SAT; GPA; GPErik; GpMiIII; GPSAT; GYPA; HGpMiIII; HGpMiV; HGpMiX; HGpMiXI; HGpSta(C); MNS; CD235a; MN |
Species | Human |
Expression System | HEK293 |
Tag | C-hFc |
Expression Range | Ser20-Glu91 |
Mol. Weight | The protein has a predicted MW of 34.7 kDa. Due to glycosylation, the protein migrates to 45-70 kDa based on Tris-Bis PAGE result. |
Form | Lyophilized |
Formulation | Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
Endotoxin | Less than 1EU per ug by the LAL method. |
Activity | The affinity constant of 0.72 uM as determined in SPR assay (Biacore T200). Contact us for detailed testing images. |
Storage | Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
Shipping | Shipped at ambient temperature. |
Gene Background | Granulomatosis with polyangiitis (GPA) presents a wide spectrum of manifestations from the common respiratory symptoms to infrequent neurological and cardiac complications. The challenge in diagnosis and management makes the rapidly progressive disorder one of the most challenging dilemmas in clinical medicine.The ultimate goal is an improved prognosis through outcome measures which assesses the disease control with minimal adverse effects of intensive immunosuppressive regimens, an integral part of the clinical approach to improve the quality of life of GPA patients. |